Vepdegestrant (ARV-471), a PROTAC protein degrader targeting estrogen receptor degradation, is used to treat patients with locally advanced or metastatic ER+/HER2– breast cancer (Nieto-Jiménez et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.